South Korea
· Delayed Price · Currency is KRW Biotoxtech Statistics
Total Valuation
Biotoxtech has a market cap or net worth of KRW 68.57 billion. The enterprise value is 89.15 billion.
| Market Cap | 68.57B |
| Enterprise Value | 89.15B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biotoxtech has 15.93 million shares outstanding. The number of shares has increased by 7.88% in one year.
| Shares Outstanding | 15.93M |
| Shares Change (YoY) | +7.88% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 14.54% |
| Owned by Institutions (%) | 0.20% |
| Float | 10.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.99 |
| PB Ratio | 1.41 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -18.04 |
| EV / Sales | 2.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.10 |
Financial Position
The company has a current ratio of 0.75, with a Debt / Equity ratio of 1.37.
| Current Ratio | 0.75 |
| Quick Ratio | 0.53 |
| Debt / Equity | 1.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | -6.58 |
| Interest Coverage | -2.46 |
Financial Efficiency
Return on equity (ROE) is -20.68% and return on invested capital (ROIC) is -6.80%.
| Return on Equity (ROE) | -20.68% |
| Return on Assets (ROA) | -5.09% |
| Return on Capital (ROIC) | -6.80% |
| Revenue Per Employee | 161.10M |
| Profits Per Employee | -23.10M |
| Employee Count | 214 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 2.94 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.11% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -38.11% |
| 50-Day Moving Average | 4,625.80 |
| 200-Day Moving Average | 5,427.70 |
| Relative Strength Index (RSI) | 51.23 |
| Average Volume (20 Days) | 116,204 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biotoxtech had revenue of KRW 34.47 billion and -4.94 billion in losses. Loss per share was -333.69.
| Revenue | 34.47B |
| Gross Profit | -127.70M |
| Operating Income | -10.76B |
| Pretax Income | -12.20B |
| Net Income | -4.94B |
| EBITDA | -6.84B |
| EBIT | -10.76B |
| Loss Per Share | -333.69 |
Balance Sheet
The company has 31.42 billion in cash and 58.09 billion in debt, giving a net cash position of -26.66 billion or -1,674.01 per share.
| Cash & Cash Equivalents | 31.42B |
| Total Debt | 58.09B |
| Net Cash | -26.66B |
| Net Cash Per Share | -1,674.01 |
| Equity (Book Value) | 42.41B |
| Book Value Per Share | 3,044.49 |
| Working Capital | -18.13B |
Cash Flow
In the last 12 months, operating cash flow was -8.58 billion and capital expenditures -245.34 million, giving a free cash flow of -8.83 billion.
| Operating Cash Flow | -8.58B |
| Capital Expenditures | -245.34M |
| Free Cash Flow | -8.83B |
| FCF Per Share | -554.26 |
Margins
Gross margin is -0.37%, with operating and profit margins of -31.22% and -14.34%.
| Gross Margin | -0.37% |
| Operating Margin | -31.22% |
| Pretax Margin | -35.38% |
| Profit Margin | -14.34% |
| EBITDA Margin | -19.85% |
| EBIT Margin | -31.22% |
| FCF Margin | -25.61% |
Dividends & Yields
Biotoxtech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.88% |
| Shareholder Yield | -7.88% |
| Earnings Yield | -7.75% |
| FCF Yield | -12.87% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biotoxtech has an Altman Z-Score of 0.5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.5 |
| Piotroski F-Score | n/a |